Exelixis
EXEL
#1347
Rank
โ‚น1.461 T
Marketcap
โ‚น5,989
Share price
-1.82%
Change (1 day)
60.23%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2026 (TTM): โ‚น99.76 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚น2.49 Billion. In 2025 the company made an earning of โ‚น87.21 Billion, an increase over its 2024 earnings that were of โ‚น63.16 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) โ‚น99.76 B14.4%
2025 โ‚น87.21 B38.08%
2024 โ‚น63.16 B164.69%
2023 โ‚น23.86 B9.89%
2022 โ‚น21.71 B-20.33%
2021 โ‚น27.25 B124.82%
2020 โ‚น12.12 B-67.14%
2019 โ‚น36.88 B-11.94%
2018 โ‚น41.89 B185.09%
2017 โ‚น14.69 B-325.82%
2016 -โ‚น6.51 Billion-58.12%
2015 -โ‚น15.54 Billion-37.61%
2014 -โ‚น24.9 Billion9.75%
2013 -โ‚น22.69 Billion65.96%
2012 -โ‚น13.68 Billion-291.63%
2011 โ‚น7.13 B-195.59%
2010 -โ‚น7.47 Billion-42.17%
2009 -โ‚น12.91 Billion-18.98%
2008 -โ‚น15.93 Billion-6.99%
2007 -โ‚น17.13 Billion46.3%
2006 -โ‚น11.71 Billion33.25%
2005 -โ‚น8.79 Billion-30.92%
2004 -โ‚น12.72 Billion44.29%
2003 -โ‚น8.82 Billion12.86%
2002 -โ‚น7.81 Billion22.79%
2001 -โ‚น6.37 Billion60.14%
2000 -โ‚น3.98 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
โ‚น1.734 T 1,656.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น645.65 B 553.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1.024 T 936.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น721.63 B 630.69%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น622.95 B 530.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น1.050 T 963.20%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น662.93 B 571.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น0.79 Billion-100.79%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น2.7 Billion-102.72%๐Ÿ‡บ๐Ÿ‡ธ USA